Cited by 76Antifungal resistance and susceptibilityNosocomial Infections in ICUFungal Infections and Studies

Invasive Fungal Infections in the Intensive Care Unit

Ostrosky-Zeichner, Luis, Al-Obaidi, Mohanad·2017·Infectious Disease Clinics of North America

Abstract

Patients in the intensive care unit are exposed to multiple stressors that predispose them to invasive fungal infections (IFIs), which carry high morbidity and mortality. Getting acquainted with the diagnostic methods and therapies is imperative for patient safety and for providing high-quality health care. This article focuses on the most frequent IFIs: invasive candidiasis and invasive aspergillosis.

Integrity signals

Registry

Crossref · 10.1016/j.idc.2017.05.005

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is an increasing incidence of azole resistance particularly among non-albicans Candida species.

    “The most recent Infectious Disease Society of America (IDSA)125 and European guidelines126,127 recommend echinocandins as first-line initial treatment for most invasive candidiasis in both neutropenic and non-neutropenic patients prior to identification to the species level due to their broad spectrum of activity, favorable side effect profile, mortality benefit, and the increasing incidence of az”

    From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [128]

  • Echinocandins have a broad spectrum of activity, favorable side effect profile, and mortality benefit in invasive candidiasis.

    “The most recent Infectious Disease Society of America (IDSA)125 and European guidelines126,127 recommend echinocandins as first-line initial treatment for most invasive candidiasis in both neutropenic and non-neutropenic patients prior to identification to the species level due to their broad spectrum of activity, favorable side effect profile, mortality benefit, and the increasing incidence of az”

    From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [128]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ostrosky-Zeichner, L., & Al-Obaidi, M.
Venue
Infectious Disease Clinics of North America
Publisher
Elsevier BV
Published
2017-09
Volume
31
Issue
3
Pages
475-487
ISSN
0891-5520 (ISSN-L)
OpenAlex
W2727739614
Cited by
76
References
84
Citations by year
2026: 4 · 2025: 3 · 2024: 21 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 6 · 2019: 10 · 2018: 3 · 2017: 1
FWCI
0.84
Type
journal article
Language
en
Open access
closed
Locations
  • Infectious Disease Clinics of North America (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
invasive fungal infections, intensive care unit, invasive candidiasis, invasive aspergillosis, critically ill patients, diagnostic methods, antifungal therapy, patient safety
MeSH terms
Invasive Fungal Infections, Antifungal Agents, Humans, Intensive Care Units, Risk Factors, Disease Management, Molecular Diagnostic Techniques, Invasive Pulmonary Aspergillosis, Candidiasis, Invasive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review